A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce the ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

MBX 1416 is an investigational long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist in development as a potential ...

Wegovy is the world’s first weekly glucagon-like peptide-1 receptor agonist for long-term weight management. China’s National ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

Mohammad Ali Sheffeh, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among ...

The two strategies, used to reduce renal, brain, and heart injury after surgery, were ineffective, but the story isn’t done.

Semaglutide key ingredients in popular weight loss drugs Ozempic and Wegovy can curb alcohol cravings as per a new study Read ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

About The Article: This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA ...

Kennedy Jr., who has been tapped by Trump to lead the HHS, has been critical of Ozempic and other weight loss drugs.

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.